Cambrex High Point Achieves Regulatory Milestones to Expand Manufacturing Capacity for Pharmaceuticals

Cambrex High Point Achieves New Regulatory Success

Cambrex, a prominent player in the global contract development and manufacturing organization (CDMO) sector, recently reached a significant milestone by completing three crucial Pre-Approval Inspections (PAIs) at its High Point facility in North Carolina. The inspections were conducted by three major regulatory authorities: the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA). This accomplishment paves the way for Cambrex High Point to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, effectively positioning the facility as a vital component of Cambrex's global manufacturing network.

Importance of Pre-Approval Inspections

Pre-Approval Inspections are essential assessments performed by regulatory agencies aimed at evaluating a facility’s quality management systems, manufacturing processes, data integrity, and operational controls. Completion of these inspections is not only a regulatory necessity but also a testament to the facility’s readiness to produce commercial products.

The recent milestone follows Cambrex's $38 million expansion of the High Point site, completed in 2023. This investment enabled the addition of advanced analytical and chemical development labs, as well as clinical manufacturing suites specifically tailored for commercial operations. The facility now boasts reactors with a capacity of up to 2,000 liters, enhancing its capability to support lower-volume commercial products, including orphan drugs, precision medicines, and other specialized therapies targeted at smaller patient populations.

Strategic Implications for Cambrex

Thomas Loewald, CEO of Cambrex, expressed his pride in the High Point team’s dedication and the success of the inspections. He remarked, “Successfully completing these inspections demonstrates the strength of our quality systems and the dedication of the High Point team.” He also highlighted the industry’s growing demand for commercial manufacturing capacity at smaller scales, asserting that High Point was purpose-built to meet that need effectively, providing a flexible and efficient pathway from development to long-term commercial supply.

This development is a crucial addition to Cambrex’s global network, allowing for a streamlined process that takes customers from process development and clinical manufacturing through to commercial production. The expansion of commercial manufacturing capabilities in North Carolina establishes Cambrex’s commitment to supporting customer programs through every stage of the product lifecycle.

About Cambrex

With over 45 years of expertise, Cambrex has established itself as a leader in drug substance development and manufacturing across the entire drug lifecycle. The organization employs around 2,000 professionals, serving clients globally from locations spanning North America and Europe. Cambrex is well-recognized for its specialty technologies and capabilities, which encompass a variety of areas like continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, and material characterization.

Clearly, the successful completion of these inspections marks an important chapter for Cambrex High Point, reinforcing its role as a key player in the pharmaceutical manufacturing landscape and highlighting Cambrex’s dedication to fostering innovation and providing quality manufacturing solutions worldwide.